Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TOP1 | P11387 | 1/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 5/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | GUSB | P08236 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21450917 | 0.90 | TOP1 (0.62) | KDM4ETOP1TOP2ADPP4ADORA3 | |
| SCHEMBL17655673 | 0.87 | KDM4E (0.58) | KDM4ETOP1TOP2APIM1PIM2 | |
| SCHEMBL16339120 | 0.85 | KDM4E (0.52) | KDM4ETOP1TOP2APIM1PIM2 | |
| SCHEMBL21451065 | 0.85 | MPI (0.39) | KDM4ETOP1TOP2AIDO1ADORA3 | |
| SCHEMBL21875194 | 0.82 | KDM4E (0.55) | KDM4EADORA3ADORA2AMAPT | |
| SCHEMBL16339385 | 0.82 | KDM4E (0.49) | KDM4ETOP1TOP2APIM1PIM2 | |
| SCHEMBL30163607 | 0.82 | KDM4E (0.49) | KDM4ETOP1TOP2APIM1PIM2 | |
| SCHEMBL16374499 | 0.82 | TOP1 (0.39) | KDM4ETOP1TOP2ATLR8TLR7 | |
| SCHEMBL16338804 | 0.82 | KDM4E (0.49) | KDM4ETOP1TOP2APIM1PIM2 | |
| SCHEMBL30163600 | 0.82 | KDM4E (0.49) | KDM4ETOP1TOP2APIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332476-B2 | Fms-like tyrosine kinase inhibitors | 3SM BIOTRON INC. (TW) | 2022-05-17 | — | — | US | disclosed |
| US-11332476-B2 | Fms-like tyrosine kinase inhibitors | 3SM BIOTRON INC. (TW) | 2022-05-17 | — | — | US | disclosed |
| US-20200131194-A1 | FMS-LIKE TYROSINE KINASE INHIBITORS | Sagabio Co., Ltd. (TW) | 2020-04-30 | — | — | US | disclosed |
| US-20200131194-A1 | FMS-LIKE TYROSINE KINASE INHIBITORS | Sagabio Co., Ltd. (TW) | 2020-04-30 | — | — | US | disclosed |
| WO-2019191896-A1 | FMS-LIKE TYROSINE KINASE INHIBITORS | 3SM BIOTRON INC. (CN) | 2019-10-10 | — | — | WO | disclosed |
| EP-3002287-B1 | Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors | NAT DEFENSE MEDICAL CENTER (TW) | 2018-01-31 | — | — | EP | disclosed |
| EP-3002287-A1 | Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors | National Defense Medical Center (TW) | 2016-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332476-B2 | Fms-like tyrosine kinase inhibitors | FLT3, FLT4, FLT1 | KDM4E 1341/4885TOP1 2980/4885TOP2A 2701/4885 |
| US-20200131194-A1 | FMS-LIKE TYROSINE KINASE INHIBITORS | FLT3, FLT4, FLT1 | KDM4E 1341/4885TOP1 2980/4885TOP2A 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.